About AlivaMab Discovery Services
AlivaMab Discovery Services combines the a broadly adopted human therapeutic antibody discovery technology with discovery processes. Its end-to-end discovery workflow (including sequencing) produces fully human, functionally characterized, therapeutic antibodies in as little as 8 weeks.
Missing: AlivaMab Discovery Services's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AlivaMab Discovery Services's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AlivaMab Discovery Services
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AlivaMab Discovery Services is included in 2 Expert Collections, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Latest AlivaMab Discovery Services News
Nov 18, 2022
SAN DIEGO--(BUSINESS WIRE)-- Ablexis, LLC (“Ablexis”), a biopharmaceutical company focused on licensing its AlivaMab® Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (“ADS”), a leader in the discovery of superior antibody-based therapeutics, which together are leading providers of solutions for the discovery of superior antibody-based therapeutics, announced an expansion of platforms and capabilities in antibody drug discovery and engineering. These innovative new offerings include: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005487/en/ Molecularly diverse panels of lead-quality antibodies ready for reformatting into multispecific formats of the partner’s choice, including a large panel of T-cell-engaging CD3 antibodies that potently eliminate cancer cells with minimal cytokine release. New strains of AlivaMab XKL Mice offered by Ablexis that further expand the molecular and epitope diversity of the immune response to promote even broader responses against the increasingly complex types of antigens at the cutting edge of antibody drug discovery. NGS-based hit-expansion capabilities that expand upon ADS’ existing advanced hybridoma-based approaches, increasing captured diversity. Immune repertoire display technology offered by ADS, which enhances the capture of alternative diversities of the immune response, downstream screening, and antibody drug engineering. “Ablexis and AlivaMab Discovery Services continue to invest in new technologies that maximize value and flexibility for our partners," said Larry Green, PhD, Chief Executive Officer of Ablexis and AlivaMab Discovery Services. “Our partners enjoy an edge on their competition, not only through access to the expanding suite of AlivaMab Mouse transgenic mice for antibody drug discovery and ADS’ expanding offerings of validated technologies in antibody discovery and engineering, but also through the intellectual contributions of our scientific leadership team and deep bench of scientists. The result is that we outperform with unsurpassed speed and efficiency in the delivery of molecularly diverse, drug-quality human antibodies, even for the most challenging drug targets, enabling our partners to discover and advance better antibody drug candidates faster.” Data on these new capabilities will be highlighted in two presentations by Jane Seagal, PhD, Vice President of Antibody Discovery at ADS, at PEGS Europe, to be held at the InterContinental Barcelona from November 14 to 16, 2022. A Platform for Tuning Therapeutic Efficacy of T-Cell-Engaging Bispecific Antibodies – November 15 at 3:35 pm CET. Discovery of Diverse Antibody Panels Using AlivaMab® Mouse: The Foundation for Successful Antibody Therapeutics – November 16 at 12:15 pm CET. About Ablexis, LLC Ablexis, LLC created and non-exclusively licenses AlivaMab Mouse, an expanding suite of unique, patented next generation transgenic mice, as a platform for human therapeutic antibody discovery. Ablexis has license agreements with dozens of companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com . For inquiries, please email email@example.com . About AlivaMab Discovery Services AlivaMab Discovery Services (ADS) sets its partners’ antibody discovery programs on the fastest and most de-risked path through discovery and development. Trusted by top-tier pharmaceutical and biotechnology companies, ADS delivers drug-quality, fully human antibodies on exceptional timelines. ADS rapidly and efficiently delivers truly molecularly diverse panels of antibodies, characterized for function, kinetics, and developability, and offers downstream capabilities in antibody engineering for advanced modalities, including multispecifics and CARs. The ADS team’s experience in antibody drug discovery and development comes from many of the world’s top 15 pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech, and translates across more than 500 discovery programs and 35 clinical candidates. This experience, combined with the use of trusted, proven technologies, including Ablexis’ AlivaMab® Mouse platforms, ensures the highest probability of success. For more information, please visit www.alivamab.com or email firstname.lastname@example.org . View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005487/en/ Copyright Business Wire 2022
AlivaMab Discovery Services Frequently Asked Questions (FAQ)
Where is AlivaMab Discovery Services's headquarters?
AlivaMab Discovery Services's headquarters is located at 10581 Roselle Street, San Diego.
What is AlivaMab Discovery Services's latest funding round?
AlivaMab Discovery Services's latest funding round is Acquired.
How much did AlivaMab Discovery Services raise?
AlivaMab Discovery Services raised a total of $12.9M.
Who are the investors of AlivaMab Discovery Services?
Investors of AlivaMab Discovery Services include Ablexis.
Who are AlivaMab Discovery Services's competitors?
Competitors of AlivaMab Discovery Services include Oligomerix, Biolog, NGM Biopharmaceuticals, Raptor Pharmaceutical Corp., Potentia Pharmaceuticals and 13 more.
Compare AlivaMab Discovery Services to Competitors
Effigene Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company developing small interference RNA (siRNA)-based therapeutics to treat various human diseases.
Cell Point is a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy.
Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Oxurion is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders, and cancer.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.